Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03802604
Title Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer (PROMETEO)
Acronym PROMETEO
Recruitment Active, not recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors SOLTI Breast Cancer Research Group
Indications
Therapies
Age Groups: senior | adult
Covered Countries ESP


No variant requirements are available.